AbbVie signs potential $2.4bn cancer immunotherapy deal with...

AbbVie has signed a deal worth up to $2.4 billion with the US biotech Harpoon Therapeutics, expanding a research and licensing collaboration involving technology that trains T-cells to targ

FDA approves latest Humira near-copy, as dozens of biosimila...

The FDA has approved Pfizer’s biosimilar of AbbVie’s blockbuster Humira (adalimumab), meaning that there are now five of these cheaper near-copies teed up to compete when the originator’s p

Novartis’ Cosentyx didn’t EXCEED Humira in psoriatic arthrit...

Reata rockets on data for Nrf2 drug reacquired from AbbVie

Humira tops list of drugs with unwarranted US price hikes

ESMO 2019 roundup

The European Society for Medical Oncology (ESMO) is growing in stature, with an increasing number of oncology-focused pharma companies choosing it as a forum to reveal their latest studies.